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1. Introduction
Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorpo-
real blood purification. CRRT is usually implemented over 24 h to several days with an aim 
of gentle removal of fluid overload and excess uremic toxins, where the continuous filtration 
simulates the continuity of kidney functions. It is usually indicated in critically ill and hemo-
dynamically unstable (adult and pediatric) patients with acute kidney injury (AKI) and/or 
multiorgan failure, sepsis/shock, acute brain injury, or other causes of increased intracranial 
pressure or generalized brain edema in intensive care unit (ICU), where such patients cannot 
tolerate the relatively fast removal of fluids (and solutes) by conventional hemodialysis (HD).
Continuous renal replacement therapy witnessed significant improvement since the tech-
nique was implemented by Peter Kramer of Göttingen (Germany) in 1977 [1]. The technique 
was established when Kramer was trying to introduce a catheter into the femoral vein for 
initiating HD. Accidently, the catheter went into the femoral artery, when Kramer realized 
the value of the arterial-venous pressure difference (i.e., blood flow driven by mean arterial 
pressure) in providing ultrafiltration and convection/hemofiltration concept and the need 
of replacement solutions, which was known as “continuous arterio-venous hemofiltration 
(CAVH)”. Later, in 1987, Peter Robert Uldall (Toronto, Canada) [2] introduced the “continu-
ous veno-venous hemofiltration (CVVH)” by providing a pump and replacing the need of 
the arterial pressure, a technique that avoided (a) the potential risks and complications of 
puncturing a major artery (e.g., infection, distal thrombosis, and disconnection/bleeding) and 
(b) the possible slow or altered blood flow rates due to frequent hypotension in critically ill 
or shocked patients.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Continuous renal replacement therapy is based on four main physiologic principles. These 
are (a) diffusion, (b) ultrafiltration, (c) convection, and (d) adsorption. In clinical practice, 
there is more than one principle implemented in achieving the goals of required treatment 
(e.g., diffusion, ultrafiltration, and convection). CRRT can be performed in one or more of the 
following four modalities: (1) slow continuous ultrafiltration (SCUF), (2) continuous veno-
venous hemofiltration (CVVH), (3) continuous veno-venous hemodiafiltration (CVVHDF), 
and (4) continuous veno-venous hemodialysis (CVVHD). Other therapeutic modalities 
that can be used in conjunction with CRRT include therapeutic plasma exchange and 
hemoperfusion/adsorption.
The performance and delivery of CRRT depends on an efficient vascular access (e.g., internal 
jugular or femoral vein), specifically designed HD machines and high-flux membranes/dia-
lyzers. Synthetic and biocompatible membranes/dialyzers are capable of efficiently removing 
excess fluids and clearing small and middle-larger-size uremic toxins [3], and some have high 
adsorptive affinity to proteins, endotoxins, and inflammatory mediators (e.g., cytokines) [4]. 
Following high convective volume of ultrafiltration, the replacement/substitution solutions, 
which can be infused before (predilution) or after the dialyzer (postdilution), are sterile physi-
ological fluids [5] that consist of balanced electrolyte solutions of either lactate or bicarbonate 
base, which resembles the composition of the ultrafiltrate (but without the removed uremic 
wastes). The long duration of this extracorporeal blood purification technique, where the 
blood is in direct contact with blood tubes and dialyzer membrane for longer period than con-
ventional HD, requires continuous anticoagulation to prevent clotting and extend the circuit 
life. Heparin has been widely used, but it has been associated with increased risk of bleeding. 
Regional citrate anticoagulation (RCA) is the more preferred and recommended method of 
anticoagulation, where it has been associated with significantly less bleeding [6], less blood 
transfusion [7], and extended life of the extracorporeal circuit [8].
Initiation of CRRT is indicated in patients with (a) hemodynamic instability/shock, (b) diuretic-
resistant fluid overload, (c) severe metabolic acidosis (pH < 7.2), and (d) refractory hyperkalemia 
(K+ > 6.5). CRRT has also been considered in drug toxicity and in prevention of radiocontrast-
induced nephropathy [5]. The goals of CRRT include (i) clearance of uremic toxins, (ii) correction 
of electrolytes disturbance, (iii) acid-base balance, (iv) hemodynamic stabilization, (v) fluid 
balance, (vi) nutritional support, and (vii) removal and/or modulation of inflammatory media-
tors in septic patients. The success of CRRT depends on the prescribed and achieved dose of 
replacement/substitution fluids, treatment duration, type of dialyzer, and method and dose of 
anticoagulation, in addition to a well-established CRRT management protocol (e.g., type, size, 
length, placement and care of central lines, indications, when to start, and when to stop CRRT). 
Furthermore, the delivery and performance of CRRT requires well-trained medical and nursing 
staff.
Despite the general safety and valuable advantages, CRRT has some limitations. These include 
the requirement of a large-bore central vascular access (a risk source of infection), hypoten-
sion (decreased organ perfusion), continuous anticoagulation (inappropriate doses or inad-
equate control of anticoagulants may lead to bleeding, which is associated with a decrease 
in hemoglobin level and/or drop in blood pressure and possible need of blood transfusion, 
or clot formation that is associated with short circuit life, interruption of prescribed dose, 
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inadequate therapy, and increased cost), electrolyte imbalance (potassium, phosphorus, and 
magnesium), drug removal (e.g., antibiotics), and immobilization of the patient for prolonged 
periods [9].
However, most of these limitations can either be prevented or be controlled [10]. A drop-in 
blood pressure, though much less encountered than in intermittent HD, is usually compen-
sated for by the patient or, in some cases, requires inotropic support to maintain effective mean 
arterial pressure. Furthermore, CRRT prescription can be modified at any time during treat-
ment based on hemodynamic situation. A well-established protocol of RCA, for example, can 
help in maintaining the patency of the extracorporeal circuit for a longer period and in avoiding 
uncontrolled bleeding. Implementation of infection control policies and procedures, including 
aseptic techniques, can help in preventing or reducing the vascular access catheter-associated 
infection. Regular monitoring and assessment of electrolytes and blood gases and the selection 
of appropriate replacement solutions (e.g., bicarbonate-based buffer and required composition 
of electrolytes and supplements) not only can help in replacing plasma volume removed by 
ultrafiltration but can also ensure the correction of electrolyte and acid-base imbalances. Drug 
removal in CRRT depends on its molecular weight, the sieving coefficient, and the degree of 
protein binding. Drugs with significant protein binding are removed minimally. Some drugs 
may be removed by adsorption to the membrane. Most of the commonly used drugs, including 
antibiotics, require monitoring and dose adjustments [11]. Finally, CRRT patients are prone to 
hypothermia due to the significant volume of blood that is circulated outside the body, and 
the significant volumes of the substitution and dialysate fluid used. Although newer CRRT 
machines are equipped with blood warmers that can bring both dialysate and substitution 
fluids to 37°C (98.6°F), a close monitoring of body temperature of patients is recommended 
especially when larger volumes of substitution and dialysate solutions are used.
2. Conclusions
Severe acute kidney injury, especially when it is caused or associated with sepsis, carries 
increased risk of progression to chronic kidney disease and end-stage renal failure. In addi-
tion, it is associated with prolonged hospitalization, financial burden, and increased mortality 
rate. Critically ill patients with acute kidney injury and/or multiorgan failure in ICU require 
special modalities of therapies to ensure hemodynamic stability, euvolemic status, and acid-
base and electrolytes balance with an aim of speeding up renal recovery and avoiding del-
eterious consequences. CRRT stands as a valuable supportive therapeutic modality for such 
patients. CRRT management includes specific indications, adequate prescription, timing of 
initiation and termination, proper anticoagulation, and removal of endotoxins and inflamma-
tory mediators in different settings of associated sepsis.
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